




ELRIG

The Drug Discovery
Community

High-Content Imaging and Flow Cytometry in Drug Discovery 2025

19-20 November 2025
Stevenage, UK

#ELRIGHCI25



High-Content
Imaging and
Flow Cytometry
IN DRUG DISCOVERY

ELRIG.ORG



elrig



elrig_science



@ELRIG_SCIENCE



@elrig.org

Welcome to High-Content Imaging and Flow Cytometry in Drug Discovery 2025

We are delighted to welcome you to the ninth biennial ELRIG meeting on *High-Content Imaging and Flow Cytometry in Drug Discovery*, where scientists from academia, industry, and the technology supplier community come together to share the latest advances and applications of these powerful analytical platforms.

Flow cytometry and imaging enable high-content analysis of complex cell systems, providing invaluable insights that drive innovation across the drug discovery pipeline - from target identification and validation to clinical translation. Since our first meeting in 2010, we have witnessed remarkable progress in both technologies and their integration into research workflows.

Today, advances in machine learning and artificial intelligence are further revolutionising how researchers harness and interpret data from these systems, accelerating the pace of discovery and development.

This year's scientific programme spans three key themes:

- **Translational Flow Cytometry and Imaging in Drug Discovery and Development** - Applying these tools from the microscale and single-cell level through to complex in vitro tissue systems and clinical applications.
- **Novel and Emerging Technologies** - Showcasing next-generation instrumentation, probes, and sensors driving pharmaceutical research forward.
- **Drug Discovery in the Era of Multiomics and Spatial Cytometry** - Exploring the latest multi-parameter techniques and analytical challenges linking the genome and proteome to cellular regulation and function.

We would like to thank our conference directors - Rob Jepras (Curve Therapeutics), Niga Sirwan Nawroly (Agilent Technologies), James Pilling (AstraZeneca), Niamh Mullooly (Novo Nordisk), Richard Kasprowicz (GSK), Ben Powney (Eisai), Tim Ashlin (GSK), and Yanping Guo (UCL) - for their dedication and expertise in shaping this meeting, and the ELRIG Operations Team for their continued support.

We hope you enjoy two days of inspiring science, valuable discussion, and opportunities to connect with colleagues and exhibitors from across the imaging and cytometry community.

Conference Directors



James Pilling
AstraZeneca



Niga Sirwan Nawroly
Agilent Technologies



Rob Jepras
Curve Therapeutics



Richard Kasprowicz
GSK



Ben Powney
Eisai



Yanping Guo
UCL



Niamh Mullooly
Novo Nordisk



Tim Ashlin
GSK

Day 1 – Running Order

Conference Partner



Track Sponsor



Keynote Speaker



Kelly Zalocusky
Executive Director of
Computational Biology,
Recurison

Kelly Zalocusky, Ph.D., is Executive Director of Computational Biology, Joint Technical Team Lead of Recursion's 10-year neuroscience collaboration with Roche/Genentech, and Site Lead for Recursion's London Office. Scientifically, her focus is on deploying high-throughput imaging and AI models for novel drug development in neuroscience, and she leads scientific teams focused on applying Recursion's novel platform and approach to the discovery of therapies to radically improve patients' lives. She is a Neuroscientist by training and received her bachelor's degree from Hendrix College, and Ph.D. from Stanford University.

Time - Local	Title
08:30-09:30	Registration
09:30-09:35	GSK & ELRIG Welcome- Lisa Mohamet (GSK & ELRIG Board Member)
09:35-09:45	Conference Director Welcome & Keynote Introduction - Richard Kasprowicz (GSK)
09:45-10:30	Keynote Presentation: High content imaging and AI in the era of clinical-stage TechBio - Kelly Zalocusky (Recurison)
10:30-11:15	Refreshment Break - Sponsored by Bruker
11:15-11:20	Track Chair Welcome - Richard Kasprowicz (GSK) & Ben Powney (Eisai)
11:20-11:50	Expanding the scope of high-content imaging with bright-field - Barak Gilboa (Novo Nordisk)
11:50-11:55	Technology Spotlight - Genedata AG
11:55-12:25	High dimensional flow cytometry within an academic flow cytometry facility - Philip Hobson (Francis Crick Institute)
12:25-12:30	Technology Spotlight - terraFlow
12:30-13:45	Refreshment Break with poster session 13.00 - 13.30 - Sponsored by Bruker
13:45-13:50	Track Chair Welcome - James Pilling (AstraZeneca) & Rob Jepras (Curve Therapeutics)
13:50-14:20	Imaging flow cytometry: Innovation from discovery to the clinic - Raffaello Cimbri (AstraZeneca)
14:20-14:35	Industry Insider - Selvita Ltd
14:35-15:05	Development of dual view oblique plane microscope assays for live 3D high-content analysis and drug screening in glioblastoma spheroids - Jayne Culley (University of Edinburgh)
15:05-15:20	Industry Insider - StandardBio
15:20-15:50	Refreshment Break - Sponsored by Bruker
15:50-16:20	Conference Partner - Axxam SpA. Shaping the Future of Early Drug Discovery Through Omics and Advanced Biological Models - Fernanda Ricci
16:20-16:40	Early Career Professional Flash Poster Presentations
16:40-17:10	Platforms for the generation and high-throughput screening of cyclic peptide libraries - Cyrielle Doigneaux (Curve Therapeutics)
17:10-18:00	Inspiring Technical Careers in Industry - Yanping Guo (UCL)
17:15-19:00	Networking in The Function Room and Nucleus
17:15-18:25	Site/Lab Tours - Must be pre booked

Day 2 - Running Order

Keynote Speaker



Cecilia Johansson


Professor of Mucosal Immunology, Imperial College London

Cecilia Johansson is Professor of Mucosal immunology and Head of the Section for Respiratory Infections at the National Heart and Lung Institute (NHLI), Imperial College London. Her research group investigates how immune responses are generated and regulated through cellular crosstalk in the lung, particularly during viral infections such as respiratory syncytial virus (RSV), influenza virus and SARS-CoV-2, as well as in the contexts of vaccination and cancer.

A key focus of the lab is understanding how cytokines, such as type I interferons and IL-1, affect lung inflammation and shape both innate and adaptive immune responses. This includes exploring how these cytokines influence the initiation and progression of lung cancers. The lab uses well-established mouse models for in vivo analysis of immune responses and uses precision-cut lung slices from human tissue to support translational research.

Time - Local	Title
08:30-09:00	Registration
09:00-09:05	Conference Director Welcome & Keynote Introduction - Niga Sirwan Nawroly (Agilent Technologies)
09:05-09:50	Keynote presentation: Type I interferons in respiratory viral infections and in lung cancer - Cecilia Johansson (Imperial College London)
09:50-10:05	Industry Insider - Zeiss
10:05-10:20	Industry Insider - Araceli Biosciences
10:20-10:35	Early Career Professional Flash Poster Presentations
10:35-10:40	Best Early Career Professional Poster Award
10:40-11:20	Refreshment Break - Sponsored by Bruker
11:20-11:25	Track Chair Welcome - Niga Sirwan Nawroly (Agilent Technologies) & Niamh Mullooly (Novo Nordisk)
11:25-11:55	Advancing vaccine development through high-dimensional cellular immunoprofiling - Margherita Coccia (GSK)
11:55-12:10	Industry insider - BD Life Sciences
12:10-12:40	Uncovering novel targets in lipid modulation driving Alzheimer's disease - Elena Navarro-Guerrero (University of Oxford)
12:40-12:45	Technology Spotlight - Bruker
12:45-13:15	Advancing cell measurement: Integrating morphological profiling and AI for robust CQA assessment - Jeanne Rivera (LGC)
13:15-14:30	Refreshment Break with poster session 13.30 - 14.00 - Sponsored by Bruker
14:30-14:35	Track Chair Welcome - Yanping Guo (UCL) & Tim Ashlin (GSK)
14:35-15:05	Multimodal profiling unveils a reversible basal-like breast cancer cell state resistant to AKT inhibition - Erik Sahai (Francis Crick Institute)
15:05-15:35	Advancing organoid phenotyping through automation and high-throughput screening - Heloise Mary (Institute Of Human Biology - Roche)
15:35-16:05	Single-cell analysis in drug discovery: enhancing granularity - Carla Newman (GSK)
16:05-16:15	Conference Close - James Pilling (AstraZeneca)

Floorplan



 Agilent Agilent B10	 Araceli Biosciences Araceli Biosciences A09	 Aurora Microplates Aurora Microplates B08	 Axxam SpA Axxam SpA B06
 BD BD Life Sciences B03	 BlueCatBio BlueCatBio A04	 Cell Signaling Technology Cell Signaling Technology A07	 CURIOX Biology at its best Curiox B02
 CYTEK Transcend the conventional Cytek Biosciences B.V. B04	 Genedata Genedata B07	 INTEGRA Integra Biosciences A08	 Nikon Nikon A05
 revvity Revvity (UK) Ltd A10	 SARTORIUS Sartorius A11	 Selvita Selvita A06	 SONY Sony Europe B.V. B09
 STANDARD BIOTOOLS Standard Bio A12	 terraFlow terraFlow A03	 YOKOGAWA Yokogawa A02	 ZEISS Zeiss A01

Information for Participants

ELRIG Mobile App

Download the free ELRIG app and access all our conference information, programme and more from your phone or tablet.

- View the event programme
- View presentation and poster abstracts
- View speaker profiles
- View the exhibitor guide
- View the delegate and exhibitor list
- Organise your day with your own favourites list
- Share your profile as vCard and QR Code and scan exhibitor QR code information tags
- Network – contact delegates, other exhibitors and speakers easily through opt-in directories and integration with LinkedIn, X and Facebook.



Download our App... search for and install The Event App by EventsAir onto your mobile device, then use the Event App Code: HCI2025. For convenience, you can add the app to your device's home screen.

Wi-Fi

GSK Public Wireless

Prayer Room and Quiet Space

For a prayer room or quiet place, please ask an ELRIG member of staff.

Conference Code of Conduct

To help keep a safe space, we require the following from all attendees:

Pre-registration for the meeting is essential. At ELRIG we want all our meeting participants to enjoy, participate in and contribute to the event.

ELRIG does not accept harassment or intimidation of ELRIG participants in any form whether verbal, physical, or written (including on social media or by email).

Harassment includes, but is not limited to:

1. Offensive or unwanted conduct on the basis of age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, sex or sexual orientation which has the purpose or effect of violating dignity or creating an intimidating, hostile or degrading environment.
2. Use of sexualised or other inappropriate images or unwelcome sexualised content, inappropriate physical contact, unwelcome sexual attention or stalking.
3. Sustained interruption of speakers or those asking questions.
4. Unwanted photography or filming.

Intimidation includes, but is not limited to:

1. Making threats.
2. Bullying.
3. Personal attacks.

Participants who do not adhere to these rules will be asked to stop and expected to comply immediately. Participants may be removed from any meeting at the discretion of ELRIG's management. If you are being harassed/intimidated, notice that someone else is being harassed/intimidated, or have any other concerns, please contact any of the ELRIG management team immediately. They will be able to step in to remove you or others from a chain of communication, if this is the preferred action, and can also facilitate a discussion or mediation. If you wish, you may also nominate someone else to support facilitating any mediation or as an observer to this process.

About ELRIG

Who we are

ELRIG is a world-leading, not-for-profit organisation dedicated to advancing the drug discovery community. Our mission is to promote open access to cutting-edge research and innovation by connecting life science professionals through inclusive, free-to-attend scientific conferences and networking events.

With a dynamic community of over 25,000 members, we provide a platform for learning, collaboration, and progress on the most pressing challenges in life sciences. We are passionate about fostering diversity, inclusion, and accessibility—ensuring our events reflect a wide range of global perspectives and experiences that inspire scientific discovery and drive the industry forward.

ELRIG's Vision

To be the premier champion and enabler of an open, connected, diverse, and sustainable drug discovery and life science community.

Strategic Pillars



Enable drug discovery by improved connections between stakeholders, through an extended, sustainable, and ongoing program of best-in-class, open-access, science-based events and digital products.



Amplify scientific innovation, sector impact, and professional development by championing great science and people through platforms, recognition, and awards.



Demonstrate sector leadership in best practice for sustainability, inclusivity, representation, equality, and diversity for our teams, delegates, and target patient cohorts.

Corporate Sponsors



AstraZeneca



GSK



Pfizer

Media Partners



Codon Communications



RSK Life Science Media

FEBRUARY

WORD+ 2026*

Conference supported by ELRIG
4-5 Feb | Cambridge, UK

Advances In Cardiometabolic Disease Research Through Innovative Tools

ELRIG Forum
Feb | Copenhagen, Denmark

MARCH

Cell & Gene Therapy 2026

ELRIG Conference
9-10 March | Cambridge, UK

APRIL

Innovations In Translational Models: Replacing In Vivo Models With Complex Cellular Systems

ELRIG Forum
April | UK

MAY

Advances In Cell-based Screening In Drug Discovery

ELRIG Conference
6-7 May | Gothenburg, Sweden

JUNE

Target Innovation & Novel Screening Technologies

ELRIG Forum#
15 June | Berlin, Germany

Drug Discovery USA 2026

ELRIG Conference
16-17 June | Boston, USA

JULY

ELRIG Summer Social

1 July | Cambridge, UK

SEPTEMBER

Precision Medicine & Biomarker Discovery

ELRIG Forum
1 Sept | Belfast, UK

Translational Medicine For Women's Health

ELRIG Forum
Sept | Edinburgh, UK

OCTOBER

Drug Discovery 2026

ELRIG Conference
14-15 Oct | London, UK

NOVEMBER

Protein Sciences In Drug Discovery 2026

ELRIG Conference
Nov | Stevenage, UK

Next Gen Omics & Imaging: Single Cell And Spatial Biology

ELRIG Forum
Nov | Paris, France

DECEMBER

Meet Up

ELRIG SLAS Networking
Dec | London, UK

2026 Events

*For exhibition options contact contact@organoidspheroid.com

For exhibition options visit oxfordglobal.com/discovery-development/events/discovery-development-europe/why-sponsor